{
    "clinical_study": {
        "@rank": "111010", 
        "arm_group": {
            "arm_group_label": "carfilzomib in combination with dexamethasone", 
            "arm_group_type": "Experimental", 
            "description": "Carfilzomib will be administered at a dose of 20 mg/m2, with a dose escalation to 36 mg/m2 after Days 1 and 2 of Cycle 1 in level 1; and at a dose of 20 mg/m2, with a dose escalation to 45 mg/m2 after Days 1 and 2 of Cycle 1 in level 2 in subjects with multiple myeloma who are newly diagnosed and treatment na\u00efve. Dexamethasone will be given as a fixed dose of 20 mg PO/IV (1, 2, 8, 9, 15, 16, 22, and 23) for cycles 1 to 4 and for subsequent cycles."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and tolerability of increasing doses of\n      carfilzomib in combination with dexamethasone"
        }, 
        "brief_title": "Study of Carfilzomib in Combination w/ Dexamethasone in Patients W/Newly Diagnosed Multiple Myeloma", 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must have newly diagnosed multiple myeloma IgG, IgA, IgE or IgD by the\n             International Myeloma Foundation (IMF) 2003 Diagnostic Criteria\n\n          -  Subjects must be treatment na\u00efve.\n\n          -  Patient must not have been previously treated with any prior systemic therapy for the\n             treatment of multiple myeloma.\n\n          -  Prior treatment of hypercalcemia or spinal cord compression with corticosteroids does\n             not disqualify the patient (the dose should not exceed the equivalent of 160 mg of\n             dexamethasone in a 2 week period).\n\n          -  Patients treated with local radiotherapy with or without concomitant exposure to\n             steroids, for pain control or management of cord/nerve root compression, are\n             eligible.\n\n          -  One week must have lapsed since last date of radiotherapy, which is recommended to be\n             a limited field.\n\n          -  Patients who require concurrent radiotherapy should have entry to the protocol\n             deferred until the radiotherapy is completed and one week have passed since the last\n             date of therapy.\n\n          -  Voluntary written informed consent before performance of any study-related procedure\n             not part of normal medical care, with the understanding that consent may be withdrawn\n             by the subject at any time without prejudice to future medical care.\n\n          -  All necessary baseline studies for determining eligibility must be obtained within 21\n             days prior to enrollment.\n\n          -  Age 18 years at the time of signing Informed Consent.\n\n          -  Life expectancy of more than three months.\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 or Karnofsky\n             performance status of \u2265 60.\n\n          -  Subject must be able to adhere to the study visit schedule and other protocol\n             requirements.\n\n          -  Written informed consent in accordance with federal, local, and institutional\n             guidelines.\n\n          -  Female subjects of child-bearing potential must have a negative serum pregnancy test\n             within seven days of the first dose and agree to use dual methods of contraception\n             during and for 3 months following last dose of drug.\n\n          -  Post menopausal females (> 45 years old and without menses for > 1 year) and\n             surgically sterilized females are exempt from a pregnancy test.\n\n          -  Male subjects must use an effective barrier method of contraception during study and\n             for three months following the last dose if sexually active with a female of\n             child-bearing potential.\n\n          -  Subjects must be able to receive outpatient treatment and laboratory monitoring at\n             the institute that administers agent.\n\n        Exclusion Criteria:\n\n          -  Patient has > Grade 2 peripheral neuropathy on clinical examination within 14 days\n             before enrollment.\n\n          -  Renal insufficiency as measured by calculated creatinine clearance <15 mL/min by\n             Cockroft-Gault formula).\n\n          -  Subjects with evidence of mucosal or internal bleeding and/or platelet refractory\n             (i.e., unable to maintain a platelet count 50,000 cells/mm3).\n\n          -  Subjects with an absolute neutrophil count (ANC) < 1000 cells/mm3. Growth factors may\n             not be used to meet ANC eligibility criteria.\n\n          -  Total bilirubin > 2.0 mg/dL or bilirubin \u2265 2 x ULN\n\n          -  Subjects with a hemoglobin < 8.0 g/dL (Transfusion are permitted).\n\n          -  ALT (SGPT) > 2.5 x ULN.\n\n          -  AST \u2265 2.5 x ULN.\n\n          -  Major surgery within three weeks of starting study drug (Cycle 1 Day 1).\n\n          -  Myocardial infarction within 6 months prior to enrollment or has New York Heart\n             Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe\n             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute\n             ischemia or active conduction system abnormalities. Prior to study entry, any ECG\n             abnormality at screening has to be documented by the investigator as not medically\n             relevant.\n\n          -  Clinically relevant active infection requiring either oral or intravenous antibiotics\n             or antifungal agents\n\n          -  Serious co-morbid medical conditions such as chronic obstructive or chronic\n             restrictive pulmonary disease, and cirrhosis.\n\n          -  Any condition, including laboratory abnormalities, that in the opinion of the\n             Investigator places the subject at unacceptable risk if he/she were to participate in\n             the study.\n\n          -  Prior malignancy (within the last 3 years) except for adequately treated basal cell\n             or squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, in situ\n             prostate cancer or if the expected survival from other malignancy is less than 90% at\n             5 years\n\n          -  Uncontrolled diabetes mellitus (Fasting Blood Sugar > 400 despite medical treatment)\n\n          -  Known history of POEMS syndrome (plasma cell dyscrasia with polyneuropathy,\n             organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes).\n\n          -  Known HIV infection\n\n          -  Known active hepatitis B or C viral infection\n\n          -  Plasma cell leukemia\n\n          -  Glucocorticoid therapy (prednisone >20 mg/day or equivalent) within the last three\n             weeks\n\n          -  Any prior treatment for multiple myeloma with standard regimens or investigative\n             regimens\n\n          -  Subjects with treatment related myelodysplastic syndrome\n\n          -  Subjects in whom the required program of oral and intravenous fluid hydration is\n             contraindicated, e.g., due to pre-existing significant pulmonary, cardiac or renal\n             impairment\n\n          -  Subjects with known primary amyloidosis\n\n          -  Female subject is pregnant or breast-feeding\n\n          -  Serious medical or psychiatric illness likely to interfere with participation in this\n             clinical study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "55", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01969565", 
            "org_study_id": "IRB00060113", 
            "secondary_id": "ISTCAR511"
        }, 
        "intervention": [
            {
                "arm_group_label": "carfilzomib in combination with dexamethasone", 
                "intervention_name": "Carfilzomib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "carfilzomib in combination with dexamethasone", 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "contact": {
                "email": "jlkaufm@emory.edu", 
                "last_name": "Jonathan Kaufman, MD", 
                "phone": "404-778-1900"
            }, 
            "facility": {
                "address": {
                    "city": "Atlanta", 
                    "country": "United States", 
                    "state": "Georgia", 
                    "zip": "30022"
                }, 
                "name": "WinshipCancer Institute-Emory University"
            }, 
            "investigator": {
                "last_name": "Jonathan Kaufman, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "IST CAR 511: An Open-label, Single-arm, Phase 1b/ 2 Study of Carfilzomib in Combination With Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma", 
        "overall_contact": {
            "email": "jlkaufm@emory.edu", 
            "last_name": "Jonathan Kaufman, MD", 
            "phone": "404-778-1900"
        }, 
        "overall_official": {
            "affiliation": "Emory University", 
            "last_name": "Jonathan Kaufman, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Adverse events will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA) adverse event dictionary. The results will be tabulated to examine their frequency, organ systems affected, and relationship to study treatment. The results of laboratory assessments will be evaluated similarly.\nThe study is designed to evaluate the efficacy and safety of carfilzomib in combination with dexamethasone. Carfilzomib will be administered at a dose of 20 mg/m2, with a dose escalation to 36 mg/m2 after Days 1 and 2 of Cycle 1 in level 1; and at a dose of 20 mg/m2, with a dose escalation to 45 mg/m2 after Days 1 and 2 of Cycle 1 in level 2 in subjects with multwill be given as a fixed dose of 20 mg PO/IV (1, 2, 8, 9, 15, 16, 22, and 23) for cycles 1 to 4 and for subsequent cycles.iple myeloma who are newly diagnosed and treatment na\u00efve. Dexamethasone", 
                "measure": "Tolerability and safety of incresing doses of carfilzomib in combination with dexamethasone.", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }, 
            {
                "description": "The overall response rate will be estimated based on the crude proportion of subjects for whom best overall response is sCR, CR, VGPR, and PR.", 
                "measure": "Phase 2: Patients with >= VGPR(Very Good Primary Response)", 
                "safety_issue": "Yes", 
                "time_frame": "4 months-8months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01969565"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Emory University", 
            "investigator_full_name": "Jonathan Kaufman", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Overall response rate (ORR), defined as sCR, CR, VGPR, and PR at 4 cycles", 
            "safety_issue": "Yes", 
            "time_frame": "4 months"
        }, 
        "source": "Emory University", 
        "sponsors": {
            "collaborator": {
                "agency": "Onyx Therapeutics, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Emory University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}